Krystal Biotech, Inc. KRYS Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s change in accrued liabilities?
- Krystal Biotech, Inc. (KRYS) reported change in accrued liabilities of -$6.31M in Q1 2026.
- How has Krystal Biotech, Inc.'s change in accrued liabilities changed year-over-year?
- Krystal Biotech, Inc.'s change in accrued liabilities decreased by 270.8% year-over-year, from $3.7M to -$6.31M.
- What is the long-term trend for Krystal Biotech, Inc.'s change in accrued liabilities?
- Over 2 years (2022 to 2025), Krystal Biotech, Inc.'s change in accrued liabilities has grown at a 72.5% compound annual growth rate (CAGR), from $5.17M to $15.4M.
- What does change in accrued liabilities mean?
- The change in expenses incurred but not yet paid.
- How do you interpret change in accrued liabilities?
- An increase acts as a source of cash, while a decrease represents a cash outflow as the company settles its accrued obligations.
- How does change in accrued liabilities compare across companies?
- A standard working capital metric used to assess short-term cash management efficiency.